Diana R Withrow1, Lindsay M Morton2, Rochelle E Curtis2, Sara J Schonfeld2, Amy Berrington de González2. 1. Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. diana.withrow@nih.gov. 2. Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Abstract
PURPOSE: Radiotherapy for ductal carcinoma (DCIS) is increasing, but the risks and benefits of the treatment remain uncertain. We aimed to investigate the relationship between radiotherapy for DCIS and risk of second non-breast cancers in a large US cohort. METHODS: We conducted a retrospective cohort study of 52,556 women in 12 U.S. population-based cancer registries diagnosed with first primary DCIS during 1992-2008 at age 25-79 years. We estimated relative risks (RRs), attributable risks (AR), and excess absolute risks (EAR) of second non-breast cancers associated with radiotherapy using Poisson regression adjusted for age at year of diagnosis, grade, hormonal therapy (yes/no or unknown), and time since diagnosis. RESULTS: Approximately half of the women (46.3%) received radiotherapy. Radiotherapy was associated with an increased risk of all second non-breast cancers combined [RR 1.17, 95% confidence interval (CI) 1.08-1.28] and all in-field, radiation-related second cancers combined (RR 1.37, 95% CI 1.15-1.63), driven by second lung cancers (RR 1.33, 95% CI 1.10-1.60) and non-CLL leukemia (RR 1.71, 95% CI 1.02-2.86). The estimated cumulative excess risk of all second non-breast cancers was 0.8% by 15 years after DCIS diagnosis. CONCLUSIONS: Radiotherapy was associated with an increased risk of second non-breast cancers. The specific excess of cancers at sites likely in/near the radiotherapy field suggests the findings are unlikely due exclusively to confounding, but further research into factors related to receipt of radiotherapy is needed. Our risk estimates can be used to help assess the balance of the risks and benefits of radiotherapy for DCIS and to inform clinical practice.
PURPOSE: Radiotherapy for ductal carcinoma (DCIS) is increasing, but the risks and benefits of the treatment remain uncertain. We aimed to investigate the relationship between radiotherapy for DCIS and risk of second non-breast cancers in a large US cohort. METHODS: We conducted a retrospective cohort study of 52,556 women in 12 U.S. population-based cancer registries diagnosed with first primary DCIS during 1992-2008 at age 25-79 years. We estimated relative risks (RRs), attributable risks (AR), and excess absolute risks (EAR) of second non-breast cancers associated with radiotherapy using Poisson regression adjusted for age at year of diagnosis, grade, hormonal therapy (yes/no or unknown), and time since diagnosis. RESULTS: Approximately half of the women (46.3%) received radiotherapy. Radiotherapy was associated with an increased risk of all second non-breast cancers combined [RR 1.17, 95% confidence interval (CI) 1.08-1.28] and all in-field, radiation-related second cancers combined (RR 1.37, 95% CI 1.15-1.63), driven by second lung cancers (RR 1.33, 95% CI 1.10-1.60) and non-CLL leukemia (RR 1.71, 95% CI 1.02-2.86). The estimated cumulative excess risk of all second non-breast cancers was 0.8% by 15 years after DCIS diagnosis. CONCLUSIONS: Radiotherapy was associated with an increased risk of second non-breast cancers. The specific excess of cancers at sites likely in/near the radiotherapy field suggests the findings are unlikely due exclusively to confounding, but further research into factors related to receipt of radiotherapy is needed. Our risk estimates can be used to help assess the balance of the risks and benefits of radiotherapy for DCIS and to inform clinical practice.
Entities:
Keywords:
Breast neoplasms; Ductal carcinoma in situ; Radiotherapy; Second cancers
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Jennifer L Malin; Katherine L Kahn; John Adams; Lorna Kwan; Marianne Laouri; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2002-06-05 Impact factor: 13.506
Authors: Emma J Groen; Lotte E Elshof; Lindy L Visser; Emiel J Th Rutgers; Hillegonda A O Winter-Warnars; Esther H Lips; Jelle Wesseling Journal: Breast Date: 2016-09-23 Impact factor: 4.380
Authors: Christina A Dilaveri; Nicole P Sandhu; Lonzetta Neal; Michelle A Neben-Wittich; Tina J Hieken; Maire Brid Mac Bride; Dietlind L Wahner-Roedler; Karthik Ghosh Journal: Int J Womens Health Date: 2014-11-19
Authors: A Berrington de Gonzalez; R E Curtis; E Gilbert; C D Berg; S A Smith; M Stovall; E Ron Journal: Br J Cancer Date: 2009-11-24 Impact factor: 7.640
Authors: Maeve Mullooly; Diana R Withrow; Rochelle E Curtis; Shaoqi Fan; Linda M Liao; Ruth M Pfeiffer; Amy Berrington de González; Gretchen L Gierach Journal: Breast Cancer Res Treat Date: 2019-10-17 Impact factor: 4.872
Authors: Anna-Karin Wennstig; Charlotta Wadsten; Hans Garmo; Mikael Johansson; Irma Fredriksson; Carl Blomqvist; Lars Holmberg; Greger Nilsson; Malin Sund Journal: NPJ Breast Cancer Date: 2021-06-01